The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Picking posts and posters apart is an irritating trend in chatboards. Wholly unnecessary and tiresome.
Comes with territory unfort. it seems.
Btw on another tack I am heartened by your optimism Porky.
And the info re. Nov’s warchest ( Harchris I think). I do agree that it won’t be until H1 financials are released that there will be any clarity or moving on. Too long for me but it’ll just sit in bottom drawer regardless.
Not much of import in this post. Wet Saturday May. evening after freezing April :-(
Biosynex made 75m€ in Q1 2021
2020 results : 153.9m€ (+338% comparés to 2019)
Net result 2020 : 31m€
Net margins 34%
Dividende : 0.2€ per share
10m shares only
******************
Yes, but by made you mean turn over. They are a good comparator though.
2020 - Biosyn Rev €154m, EBITDA €52m vs Nov Rev €312m, EBITDA €210m. So revenue was about double but EBITDA quadruple. However Q1 Biosyn €75m vs Nov €83m so you could argue biosynex is moving in the right direction.
Mcap Biosyn €266m vs Nov €339m.
A quick snapshot and you might think novacyt's share price isn't that egregious after all, but the difference in the amount of money actually being made is stark. We know novacyt has a war chest building up whilst Biosynex are still having to raise funds (as recently as January).
It's one of hundreds of examples, little point in comparing. I have seen so many now that i have lost count.
There is no logic to our Share Price being this low other than its been shorted and traded to death. Put simply, It does not reflect the true value of the business - simple.
Question is what can be done about it? A move off the Bourse and Aim would be my call frankly however, with so much news and updates due at any moment it should be a matter of time before the values are properly reflected. Uncertainty will be removed at least. Time will tell.
I continue to add with the confidence that the position will change soon. GM must be aware of this situation now and its not good for the business to have a market cap this low especially as they want to make material acquisitions going forward not to mention the fact that GM intends to position the business as a mid cap.
Lets see where we are after the H1, at least we will have full clarity of the businesses full position at that point. I am currently trying to look at the current low share price as a short window buying opportunity. I'm buying into the shorts anyhow confident it will rally on news.
GLA
Hi Brookr
Important to understand that share price is not what one should compare between listed companies as this depends on the number of shares in circulation. Market cap is the true comparison that should be made (together with turnover/profit). :)
@roleybirkin
OMG - I 'm expecting another repeat of ' This is Your Life '.
Wonder if the Martial Arts will be mentioned again ?
crl123 you state in one post:-
Market abuse.
Trading houses and shorters control price via algorhythm trades and force it down.
Market is corrupt and abuses share prices. Normal and common practice.
Because of being a traders’ and shorters’ puppet
--------------------------------------------------------------------------------------------------------------
I am guessing you work in The City with such understanding of the way the markets work...
Biosynex made 75m€ in Q1 2021
2020 results : 153.9m€ (+338% comparés to 2019)
Net result 2020 : 31m€
Net margins 34%
Dividende : 0.2€ per share
10m shares only
Market abuse. Loss of gov contract 50% of revenue and uncertainty over Q4 ‘20 revenue. Overreacted and played. Trading houses and shorters control price via algorhythm trades and force it down. No debt. Cash rich. Uncertainty ( normal level in reality) and large number of nervous p/i’s who make up the shareholders. Prime bait.
Still uncertainty.
But the last company RNS gives a lot of info.
Market is corrupt and abuses share prices. Normal and common practice. See 4D pharma this week. And SNG. Also puppets.
Share price does not reflect reality nor true value here.
Because of being a traders’ and shorters’ puppet this is a share to just sensibly mothball indefinitely (patiently or impatiently. )
I find it hard to understand why the SP is where it is! Take a look at Biosynex which is in a similar market. It has a turnover of 4.27Mill Euro and a midcap of 268 Mill Euro, yet their SP is 26 Euro. Makes no sense!